{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"The study of BL22 has expired and MedImmune, the sponsor, is not interested in producing any new supply. All data has been analyzed and reviewed. All patients have been taken off study."},"pointOfContact":{"email":"kreitman@mail.nih.gov","organization":"National Cancer Institute, National Institutes of Health","phone":"301-496-6947","title":"Robert J. Kreitman, M.D."}}